دورية أكاديمية
أعرض في EDS

Breast cancer burden in eastern Sudan: seven-year retrospective study.

التفاصيل البيبلوغرافية
العنوان: Breast cancer burden in eastern Sudan: seven-year retrospective study.
المؤلفون: Ahmed ABM; Faculty of Medicine, University of Khartoum, Khartoum 11111, Sudan., Alrawa S; Faculty of Medicine, University of Khartoum, Khartoum 11111, Sudan., Yeddi AA; Faculty of Medicine, University of Khartoum, Khartoum 11111, Sudan., Alfadul ESA; Faculty of Medicine, University of Khartoum, Khartoum 11111, Sudan., Allah HMAA; East Oncology Center, Ministry of Health, Gadarif 11111, Sudan., Ahmed MBM; Faculty of Medicine, University of Khartoum, Khartoum 11111, Sudan.; East Oncology Center, Ministry of Health, Gadarif 11111, Sudan.; Faculty of Medicine and Health Sciences, University of Gadarif, Gadarif 11111, Sudan.
المصدر: Ecancermedicalscience [Ecancermedicalscience] 2024 May 21; Vol. 18, pp. 1704. Date of Electronic Publication: 2024 May 21 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: ecancer Country of Publication: England NLM ID: 101392236 Publication Model: eCollection Cited Medium: Print ISSN: 1754-6605 (Print) Linking ISSN: 17546605 NLM ISO Abbreviation: Ecancermedicalscience Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: Bristol, UK : ecancer
Original Publication: Bristol, UK : Cancer Intelligence
مستخلص: Background: Breast cancer (BC) is prevalent in Sudan, yet data on its epidemiology in Eastern Sudan is limited. This study aims to provide insights into the demographic and clinicopathologic features of BC patients treated at the East Oncology Centre (EOC) in Gadarif State, Eastern Sudan. Furthermore, we aim to identify the factors that contribute to a late-stage diagnosis.
Methods: This cross-sectional study included patients diagnosed with BC and treated in the EOC between 2016 and 2022. Data obtained from medical records were analysed using R software, with descriptive statistics and multiple logistic regressions applied to determine determinants of advanced-stage presentation. A p -value < 0.05 was considered statistically significant.
Results: Among the 394 patients studied, the majority were women (96%), married (66%) and from rural areas (43%). The peak years for BC diagnoses were 2018 and 2022, with a median age at diagnosis of 48 years. A family history of cancer was reported by 20% of patients. Clinical stages were distributed as follows: I (1.6%), II (17%), III (50%) and IV (32%). Twenty-five percent tested positive for human epidermal growth factor receptor 2, while 73% tested negative and 43% had triple-negative BC. Modified radical mastectomy was performed in 47% of patients, with 21% undergoing breast-conserving surgery. Treatment rates were 38% for radiotherapy, 84% for chemotherapy and 46% for hormonal therapy. Higher grade BC and lower education levels were associated with advanced-stage presentation, while a family history of cancer reduced the risk of advanced-stage disease (OR: 0.38, 95% CI: 0.18-0.78).
Conclusion: The study found that females in East Sudan often present at a young age and advanced stage, with a significant prevalence of triple-negative BC. Notably, family cancer history exhibited a protective effect against advanced-stage presentation, while grade 3 cancer was positively associated with advanced disease.
Competing Interests: The authors declare that they have no conflict of interest.
(© the authors; licensee ecancermedicalscience.)
References: JAMA Oncol. 2019 Nov 01;5(11):1589-1596. (PMID: 31536134)
Sci Rep. 2021 Mar 18;11(1):6360. (PMID: 33737705)
Hereditary Genet. 2013;2013(Suppl 2):. (PMID: 25285241)
JCO Glob Oncol. 2021 Feb;7:324-332. (PMID: 33617296)
Int J Surg. 2010;8(6):448-52. (PMID: 20601253)
Breast Cancer Res. 2010;12(4):207. (PMID: 20804570)
Lancet Glob Health. 2016 Dec;4(12):e923-e935. (PMID: 27855871)
Cancer Epidemiol. 2021 Dec;75:102050. (PMID: 34706325)
J Clin Oncol. 2011 Nov 20;29(33):4381-6. (PMID: 21969512)
BMC Pregnancy Childbirth. 2022 Nov 16;22(1):844. (PMID: 36384519)
Breast Cancer Res. 2019 Mar 12;21(1):40. (PMID: 30867002)
Adv Exp Med Biol. 2017;960:571-606. (PMID: 28585217)
Int J Womens Health. 2010 Aug 09;2:77-82. (PMID: 21072300)
Sci Rep. 2022 May 19;12(1):8357. (PMID: 35589860)
J Glob Oncol. 2019 Jul;5:1-10. (PMID: 31322993)
Semin Oncol Nurs. 2017 May;33(2):141-155. (PMID: 28365057)
PLoS One. 2020 Apr 30;15(4):e0232624. (PMID: 32353069)
Cancer Med. 2014 Aug;3(4):1075-84. (PMID: 24821265)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Front Oncol. 2022 Dec 22;12:1087476. (PMID: 36620568)
Am J Public Health. 2012 Dec;102(12):2322-9. (PMID: 23078489)
JCO Glob Oncol. 2021 Mar;7:368-377. (PMID: 33689484)
Int J Cancer. 2020 Mar 1;146(5):1208-1218. (PMID: 31087650)
Breast. 2020 Dec;54:8-14. (PMID: 32866903)
BMC Cancer. 2017 Dec 1;17(1):804. (PMID: 29191181)
CMAJ. 2017 Feb 21;189(7):E268-E274. (PMID: 28246240)
Indian J Cancer. 2010 Jan-Mar;47(1):23-6. (PMID: 20071785)
JAMA Intern Med. 2018 Apr 1;178(4):494-501. (PMID: 29435563)
Curr Oncol Rep. 2019 Mar 27;21(5):41. (PMID: 30919143)
World J Clin Oncol. 2014 Aug 10;5(3):465-77. (PMID: 25114860)
Medicine (Baltimore). 2017 Apr;96(15):e6641. (PMID: 28403116)
Asian Pac J Cancer Prev. 2017 Dec 28;18(12):3201-3206. (PMID: 29281867)
فهرسة مساهمة: Keywords: Sudan; breast cancer; burden; oestrogen receptor
تواريخ الأحداث: Date Created: 20240718 Latest Revision: 20240719
رمز التحديث: 20240719
مُعرف محوري في PubMed: PMC11254413
DOI: 10.3332/ecancer.2024.1704
PMID: 39021556
قاعدة البيانات: MEDLINE
الوصف
تدمد:1754-6605
DOI:10.3332/ecancer.2024.1704